Shanghai Ark Biopharmaceutical’s AK0901 Meets Phase III Endpoints in ADHD Trial
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study...
Ark Biopharmaceutical
Shanghai Ark Biopharmaceutical Partners with Partex to Advance AI-Driven Drug Development
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has formed a strategic alliance with Germany-based Partex, an...
ArkBio Partners with SDODT to Boost ADHD Treatment Marketing and Commercialization
Shanghai Ark Biopharmaceutical Co., Ltd (ArkBio), a Chinese biopharmaceutical company, has entered into a partnership...
Shanghai Ark Biopharmaceutical Partners with WuXi STA for Commercial Supply of Ziresovir
China’s Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) has entered into a partnership with WuXi STA,...
Shanghai Ark Biopharmaceutical’s STAR Market IPO Filing Accepted, Aims to Raise $289.6 Million
Shanghai Ark Biopharmaceutical Co., Ltd’s Initial Public Offering (IPO) filing to the Shanghai Stock Exchange’s...
ArkBio and Calibr Renew Collaboration to Develop First-in-Class Respiratory Drug AK0705
Shanghai Ark Biopharmaceutical Co., Ltd announced that it has renewed its co-development collaboration with Calibr,...
Amoytop’s AK0706 Receives Clinical Trial Approval for Hepatitis B Treatment
Xiamen-based Amoytop Biotech Co. Ltd has announced receiving clinical trial approval from China’s National Medical...
CDE Prioritizes Review for Jiedi Pharma’s Mitotane and Other Key Drugs
The Center for Drug Evaluation (CDE) website indicates that market filings for several key drugs,...
Ark Biosciences’ Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection
China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its...
Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline
China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its...